MRKR - Marker Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.51
+0.05 (+0.92%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.46
Open5.48
Bid5.51 x 1400
Ask5.59 x 1100
Day's Range5.35 - 5.56
52 Week Range3.33 - 13.55
Volume259,536
Avg. Volume362,943
Market Cap250.527M
Beta (3Y Monthly)0.98
PE Ratio (TTM)N/A
EPS (TTM)-7.75
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.38
Trade prices are not sourced from all markets
  • Here's Why Marker Therapeutics Fell as Much as 11.5% Today
    Motley Fool2 days ago

    Here's Why Marker Therapeutics Fell as Much as 11.5% Today

    An abstract detailing one of the company's clinical programs was rejected from an important industry meeting.

  • Zacks.com featured expert Kevin Matras highlights: Methode Electronics, Walker & Dunlop, Marker Therapeutics, Chemed and Olympic Steel
    Zacks22 days ago

    Zacks.com featured expert Kevin Matras highlights: Methode Electronics, Walker & Dunlop, Marker Therapeutics, Chemed and Olympic Steel

    Zacks.com featured expert Kevin Matras highlights: Methode Electronics, Walker & Dunlop, Marker Therapeutics, Chemed and Olympic Steel

  • PR Newswire22 days ago

    Marker Therapeutics Provides Business and Clinical Update

    HOUSTON, March 28, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a business and clinical update, as well as an overview of upcoming milestones for 2019. "Our MultiTAA T cell therapies have continued to generate positive and compelling clinical data across various indications in several ongoing investigator-sponsored clinical trials led by Baylor College of Medicine (BCM).

  • These 5 Stocks Make Great Buys on New Analyst Coverage
    Zacks23 days ago

    These 5 Stocks Make Great Buys on New Analyst Coverage

    Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

  • Marker Therapeutics to Host Business Update Conference Call and Webcast on Thursday, March 28th
    PR Newswirelast month

    Marker Therapeutics to Host Business Update Conference Call and Webcast on Thursday, March 28th

    HOUSTON , March 18, 2019 /PRNewswire/ -- Marker Therapeutics, Inc.  (NASDAQ: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

  • PR Newswire2 months ago

    Marker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019

    HOUSTON, Feb. 25, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced updated data from four clinical trials using the Company's multi-antigen targeted T cell (MultiTAA) therapies. Among the highlights, were results from an ongoing study including patients with acute myeloid leukemia (AML), which were reviewed in an oral presentation by Dr. Premal Lulla, M.B.B.S., Assistant Professor of Medicine, Baylor College of Medicine. "We continue to be highly encouraged by the clinical results we've seen to date with our MultiTAA therapies.

  • Marker Therapeutics Congratulates Helen E. Heslop, MD, DSc (Hon) on Receiving the ASBMT Lifetime Achievement Award
    PR Newswire2 months ago

    Marker Therapeutics Congratulates Helen E. Heslop, MD, DSc (Hon) on Receiving the ASBMT Lifetime Achievement Award

    HOUSTON, Feb. 21, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Dr. Helen E. Heslop, Company co-founder and a founding member of Marker's Scientific Advisory Board, has been recognized with the ASBMT Lifetime Achievement Award at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019. The ASBMT Lifetime Achievement Award is presented annually and recognizes an individual who has made continuing contributions to the field of blood and marrow transplantation.

  • Marker Therapeutics to Present at the CAR-TCR Summit Europe
    PR Newswire2 months ago

    Marker Therapeutics to Present at the CAR-TCR Summit Europe

    HOUSTON , Feb. 20, 2019 /PRNewswire/ --   Marker Therapeutics, Inc.  (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

  • PR Newswire2 months ago

    Marker Therapeutics Announces Change in Corporate Headquarters and Access to New Laboratory Facility

    HOUSTON, Feb. 15, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company, today announced that it has formally relocated its corporate headquarters from Jacksonville, Florida to Houston, Texas. The Company also announced that it is now a resident company at Johnson & Johnson Innovation – JLABS (JLABS at TMC), an incubator located in the heart of the Texas Medical Center, to access a fully equipped laboratory to conduct research and development.

  • Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development
    PR Newswire2 months ago

    Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development

    HOUSTON, Feb. 7, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development. In this role, she will be responsible for clinical development strategy, clinical study design, and medical oversight of the Company's therapeutic product candidates.

  • Marker Therapeutics to Present at the 2019 BIO CEO & Investor Conference
    PR Newswire2 months ago

    Marker Therapeutics to Present at the 2019 BIO CEO & Investor Conference

    HOUSTON , Feb. 6, 2019 /PRNewswire/ -- Marker Therapeutics, Inc.  (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

  • Does Market Volatility Impact Marker Therapeutics, Inc.’s (NASDAQ:MRKR) Share Price?
    Simply Wall St.2 months ago

    Does Market Volatility Impact Marker Therapeutics, Inc.’s (NASDAQ:MRKR) Share Price?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Anyone researching Marker Therapeutics, Inc. (NASDAQ:MRKR) might Read More...

  • Marker Therapeutics to Present at the Phacilitate Leaders World & World Stem Cell Summit 2019
    PR Newswire3 months ago

    Marker Therapeutics to Present at the Phacilitate Leaders World & World Stem Cell Summit 2019

    HOUSTON , Jan. 17, 2019 /PRNewswire/ --  Marker Therapeutics, Inc.  (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

  • The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019
    PR Newswire3 months ago

    The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019

    HOUSTON , Jan. 15, 2019 /PRNewswire/ --  Marker Therapeutics, Inc.  (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies ...

  • PR Newswire3 months ago

    Marker Therapeutics Provides Updates of its Lead Clinical Programs

    HOUSTON, Jan. 3, 2019 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced a year-end update in five clinical trials using the Company's therapeutic products, LAPP and MAPP multi-antigen targeted T cell (MultiTAA) therapies and TPIV200, its Folate Receptor Alpha (FRα) peptide cancer vaccine product candidate.

  • ACCESSWIRE4 months ago

    These 4 Healthcare Stocks May Test December Highs

    CORAL GABLES, FL / ACCESSWIRE / December 31,2018 / This year has been a year which has seen significant market volatility, but the healthcare sector has managed to remain above the curve by constantly working to design and implement innovative approaches to medical care for patients suffering from a variety of serious illnesses. As experts and professionals in the field have worked on developing technologies to improvequality of care available for consumers, the healthcare industry, as a whole, has seen tremendous growth. Premier Health Group (PHGRF) (PHGI), Axsome Therapeutics Inc (AXSM), Marimed Inc (MRMD), and Marker Therapeutics Inc (MRKR) are 4 healthcare companies worth keeping tabs on as we head into the new year.

  • Marker Therapeutics to Present at the Tumor Targeted Lymphocytes Summit
    PR Newswire4 months ago

    Marker Therapeutics to Present at the Tumor Targeted Lymphocytes Summit

    HOUSTON , Dec. 6, 2018 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang , will present a corporate ...

  • The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th American Society of Hematology Annual Meeting
    PR Newswire5 months ago

    The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th American Society of Hematology Annual Meeting

    --Three abstracts accepted, including oral presentation on multiple myeloma clinical data-- HOUSTON , Nov. 27, 2018 /PRNewswire/ --  Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology ...

  • Marker Therapeutics, Inc. Appoints Anthony H. Kim as Chief Financial Officer
    PR Newswire5 months ago

    Marker Therapeutics, Inc. Appoints Anthony H. Kim as Chief Financial Officer

    HOUSTON, Nov. 27, 2018 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company, today announced the appointment of Anthony H. Kim as its new Chief Financial Officer. Michael J. Loiacono, who has served as the Company's Chief Financial Officer and Chief Accounting Officer since August 2016, will continue in his role as Marker's Chief Accounting Officer. "I have known Tony Kim for almost twenty years and I consider him to be one of the most talented financial professionals I've worked with during that time.

  • Marker Therapeutics to Present at Three Upcoming Healthcare Conferences
    PR Newswire5 months ago

    Marker Therapeutics to Present at Three Upcoming Healthcare Conferences

    HOUSTON , Nov. 8, 2018 /PRNewswire/ --  Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang , will participate ...

  • Marker Therapeutics, Inc. Announces New Executive Appointments
    PR Newswire6 months ago

    Marker Therapeutics, Inc. Announces New Executive Appointments

    HOUSTON, Oct. 23, 2018 /PRNewswire/ -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company, today announced the addition of four senior executives to its executive management team. Juan F. Vera, M.D., has been appointed Chief Development Officer.

  • Marker to Present at Two Upcoming Cellular Therapy Conferences
    PR Newswire6 months ago

    Marker to Present at Two Upcoming Cellular Therapy Conferences

    HOUSTON , Oct. 18, 2018 /PRNewswire/ --  Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang , will participate ...